221 CRESCENT ST., WALTHAM, MA
Underwriting Agreement with Jefferies LLC for $70.00 Share Offering
Investor Presentation
News
Provides Pipeline Progress and Reports Third Quarter 2025 Financial Results
News, Underwriting Agreement, Securities Holder Rights or Indentures, Legal Opinion
Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results
Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis
FY 2025
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Notice of Proposed Sale of Securities
Schedule 13G - Ownership Report
S-1MEF
Correspondence